创新药基金年内净值增长明显 基金经理看好产业未来发展

Core Viewpoint - The pharmaceutical sector, particularly innovative drugs, has shown strong performance in fund net value growth this year, indicating a promising future for the industry and related funds [1][2]. Fund Performance - As of June 13, 2023, 22 pharmaceutical funds have achieved a net value growth rate exceeding 50%, with themes including innovative drugs, pharmaceutical industry, and healthcare leading the rankings [2]. - In the QDII fund category, 5 pharmaceutical products also surpassed a 50% growth rate, with 3 innovative drug funds ranking among the top seven [2]. - The Hong Kong innovative drug 50 ETF has seen a significant increase in shares, growing nearly 40 million shares this year, with a share change rate of nearly 300% [2]. Market Trends - The Hong Kong innovative drug index has outperformed other industry indices, with a year-to-date increase of approximately 74%, leading among 233 industry indices [2]. - Other related indices, such as the Hang Seng Hong Kong Stock Connect Innovative Drug and Healthcare indices, have also maintained growth rates around 70% [2]. Future Outlook - Fund managers express optimism about the future of the innovative drug sector, citing factors such as low per capita medical spending and an aging population driving demand [3][4]. - The innovative drug industry is expected to enter a new valuation reassessment cycle, supported by favorable policies and advancements in AI technology [3][4]. - The market is anticipated to witness a significant transformation, with Chinese pharmaceutical companies improving their overseas production and quality, leading to a potential "turning point" in profitability [4].